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Amplification of the complement cascade on cell surfaces is mediated by the
membrane-bound C3 convertasesof the classical (C4b2a) andalternative (C3bBb)
pathways . These enzymes are assembled after the nonspecific covalent binding
of nascent C4b or C3b to acceptor molecules on the cell membranes . These
polypeptides can bind not only to foreign substrates, but also to the surface of
autologous cells in the vicinity of the site ofcomplement activation .
Until a few years ago, the mechanisms of control of the potentially harmful
C3b andC4b that bind to autologous cells were obscure . Recent evidence (1-5)
strongly suggests that the assembly of C3-convertases on these complement
fragments is inhibited by specific membrane molecules . One of them is decay-
accelerating factor (DAF),' a glycoprotein of ^-75,000 M,., found on all blood
cells, endothelial, and epithelial cells (6-10) . DAF inhibits the assembly of C3
convertases on autologous cells by binding to C4b or C3b, interfering with the
association of these complement fragments with C2 or factorB (4, 11) . However,
DAFs action is reversible and does not alter the structure of C4b or C3b . A
second inhibitor, complement receptor type I (CRI), binds to C4b and C3b,
serving as a cofactor for the cleavage and irreversible inactivation of the comple-
ment fragments by the serum enzyme C3b/C4b inactivator (I) . CRI is a glyco-
protein of ^-200,000 M, found on human erythrocytes, neutrophils, monocytes,
B (and a few T) lymphocytes, and glomerular podocytes (reviewed in 12 and 13).
Although in theory CR1 could interact with clustered C3b/C4b deposited
either on the same cell membrane (endogenous activity), or on neighboring cells
(exogenous activity), only the latter has been well documented . The purpose of
the experiments described in this paper was to determine whether CRI has
endogenous activity . We reasoned that ifCR I can move in the plane of the cell
membrane and recognize the covalently attached C4b ligand, we should be able
to detect this interaction by means of bifunctional crosslinking reagents . More-
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over, the formation of these CRI /C4b complexes within the cell membrane
might have an inhibitory effect on the exogenous cofactor activity of CR 1 .
Materials and Methods
Buffers, Antibodies, Complement Components, and Red Cell Hemolytic Intermediates.
￿
We
used isotonic veronal buffer containing 2 .47 mM sodium veronal buffer (pH 7 .3), 72 .7
mM NaCI, 2.5% dextrose, 0.1% gelatin, 0 .15 mM CaC12, and 0.5 MM MgC12 (DGVB2+);
and we brought PBS to pH 8 .3 with 0 .1 N NaOH. mAbs to human CRI (57F, 57H, and
441)) (14); to DAY (IA10, IIH' and VIIIA7) (8); and to a protein from a malaria parasite
(31)11, [15]); guinea pig C1 (16); human C4 (17), C2 (18), and C3 (17); factor I (19); and
CRI (20) were prepared as described. Rabbit anti-Forssman hemolysin was from Gibco
Laboratories (Grand Island, NY) and affinity-purified goat IgG anti-mouse IgG was
bought from Cappel Laboratories, (Cochranville, PA). Rabbit IgM antibodies to human
erythrocytes (HE) were a gift of Dr. Eric Brown (Washington University, St. Louis, MO).
IgG fractions from rabbit anti-C4 antiserum and normal rabbit serum were prepared by
DEAF-cellulose chromatography.
C3, C4, and goat IgG anti-mouse IgG were radiolabeled with "'I using lodogen (Pierce
Chemical Co., Rockland, IL)-coated test tubes. Sp act were ^-3 X 107 cpm/wg protein.
Antibody-sensitized sheep erythrocytes (SEA) bearing 300 hemolytic sites of guinea pig
Cl, human C4, and "'YC2 (SEAC 14-y2) were prepared as described (4). Radiolabeled
C36 was deposited on SE by incubating labeled C3 with SEAC14-y2 in DGVB2+ for 15
min at 30°C. HE were sensitized with a subagglutinating dose of rabbit IgM anti-HE.
Antibody-sensitized HE (HEA) were incubated with guinea pig Cl and human C4 in




HE hemolytic intermediates were suspended at 108 cells/ml in PBS (pH
8.3) containing 0.02% sodium azide. The crosslinker dithio-bis(succinimidyl propionate)
(DSP) (Pierce Chemical Co.) was dissolved at 10 mg/ml in DMSO and added to cell
suspensions at a final concentration of 100 tag/ml (21). The same amount of DMSO was
added to another sample of the cell suspension as a control. Reaction mixtures were
incubated, with rotation, for 1 h at room temperature. We stopped the reaction by adding
50 mM Tris-HCI (pH 8.0)-buffered saline and washing the cells with the same buffer.
Red cell ghosts were prepared by hypotonic lysis in 15 mM Tris-HCI buffer (pH 7.8),
followed by centrifugation at 12,000 g for 15 min. The ghosts were dissolved at a
concentration corresponding to 5 X 107 cells per 50 Wl in boiling SDS-PAGE sample
buffer (5% SDS, 125 mM Tris-HCI buffer [pH 6.8], 10% glycerol, and 0.01% bromphenol
blue). Alternatively, the ghosts were extracted with PBS containing 0.5% NP-40 and 1
mM PMSF for 20 min on ice at 108 cells per 100 Al, followed by centrifugation to remove
insoluble materials.
Removal of C4 by Immunoprecipitation.
￿
Samples of the NP-40 extract from ghosts of
DSP-treated HEAC14 bearing 1,000 molecules of C4b per cell were mixed with 10 kg of
anti-C4 IgG or normal IgG . After 15 min incubation on ice, the mixtures were added to
protein A-Sepharose CL-4 B beads (10 kl) (Pharmacia Fine Chemicals, Piscataway, NJ),
followed by 15 min incubation at 20°C . Supernatants were collected after centrifugation,
mixed with the SDS-PAGE sample buffer, and analyzed by SDS-PAGE and Western
blotting.
Detection of CRI by Western Blotting.
￿
The dissolved ghosts from DSP-treated HE
hemolytic intermediates or samples after immunoprecipitation of C4 were subjected to
SDS-PAGE on a 4 .5% gel . The samples were transferred electrophoretically to nitrocel-
lulose paper using a Bio-Rad transblot system (Bio-Rad Laboratories, Richmond, CA),
and excess binding sites on the paper were blocked with BSA. CR 1 was detected by
incubation with a mixture of anti-CRI mAbs (57F, 57H, and 441); IO )ag/ml each), and
then with "5Mabeled goat anti-mouse IgG.
Cleavage ofHE-bound C4b by Factor I.
￿
HEAC14 cells (100 Al of 108 cells/ml in DGVB2+)





Crosslinking of CRI to C4b on HE . HEAC14 cells, and HE, HEA and HEAC1
as controls were crosslinked with DSP (lanes 1-8) or mock crosslinked (lanes 9-14) and then
subjected to SDS-PAGE on a 4.5% gel, and to Western blotting . CRI was detected on the blot
by a mixture of anti-CRI mAbs followed by labeled second antibodies. Lanes 1 and 9, HE ;
lanes 2 and 10, HEA; lanes 3 and 11, HEAC1 ; lanes 4-8, crosslinked HEAC14 bearing 450,
700, 1,000, 1,500, and 1,900 molecules of C46 per cell ; lanes 12-14, mock crosslinked
HEAC14 bearing 1,000, 1,500, and 1,900 molecules of C46 per cell . High-M, complexes
containing CRI were seen only in crosslinked HEAC14 (lanes 4-8) .
(0-40 pg/ml in DGVB2'') and 50 pl of either DGVB2+, CRI (1 lAg/ml), or HE (6 X 10'
cells/ml) . After 2 h of incubation at 37 °C, 1 ml ofDGVB2+ was added, and the mixtures
were centrifuged . RadiolabeledC4 fragments released into thesupernatant were detected
in a gamma counter . In another experiment, a mixture of anti-CRI mAbs was added to
HEAC14 and factor I to determine whether the cleavage ofC4bwas CRI-dependent .
C3c-release Assayfor Exogenous CRI Activity .
￿
SEAC1423 cells bearing 1,800 molecules
of radiolabeled C3b per cell (5 X 10' cells/ml in DGVB2+ ) were mixed with factor I (5
P.g/ml) and E''°AC1 bearing various amounts of C4b (5 X 10' cells/ml) . After 60 min
incubation at 37°C the cells were pelleted by centrifugation and the amount of C3c
released into the supernatant was measured by gamma counting .
Results
Formation of CRI-C4b Complexes Within the Cell Membrane.
￿
To show the
association of CR1 with C4b within the same membrane, a crosslinking reagent
(DSP) was used . HEAC14 and control cells, HE,HEA, and HEAC1, were treated
with DSP. Western blotting analysis of solubilized cell membranes using anti-
CR1 mAbs revealed the presence of free CRI and of CRI-containing complexes
in two wide bands with high M, (>400,000) (Fig . 1) . The high-M,. bands were
present only on DSP-treated HEAC14, and not on mock-treated HEAC14 (Fig .1380
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1, lanes 12-14), or on DSP-treated HE, HEA, and HEACI (Fig. 1, lanes 1-3) .
The intensity of the high-M, bands increased in a dose-dependent fashion with
the amount of bound C4b (lanes 4-8) . The efficiency of the complex formation
was high, that is, most of the CR1 in the red cells was associated with the high-
M, bands when 1,900 molecules of C4b were deposited on HE (Fig. 1, lane 8).
The above results suggested that the high-M, bands consisted of a complex
between CRI and C4b. To demonstrate this point directly we immunoprecipi-
tated the extracts with anti-C4 antibody and Sepharose-protein A before the
Western blotting analysis. As shown in Fig. 2 (lane 1), the high-M, bands were
removed by treatment with anti-C4 but not with normal IgG (Fig. 2, lane 2). As
an additional control to show that the complexes between CR 1 and C4b were
formed within cell membranes rather than between cells, mixtures of HE and
SE bearing C4b (SEAC14) were treated with DSP, and the membranes were
subjected to Western blotting. Only free CRI was found in the radioautographs
(not shown).
Intrinsic Cofactor Activity of CR1.
￿
When HEAC14 cells bearing radiolabeled
C4b were incubated at 37°C in the presence of increasing concentrations of
factor I, C4b was cleaved and C4 fragments were released into the supernatant
in a dose-dependent fashion. The cleavage was CRI-dependent, since mAbs
against CR 1 (but not against DAF or a malaria parasite antigen) inhibited the
activity of I (Fig. 3). The pattern of fragmentation of C4b on HE was identical
to that previously observed when SE bearing C4b were treated with factor I and
CRI ; that is, C4c (M, 140,000) was released and C4d (Mr 40,000) remained
bound to the cell membrane (data not shown).
Additional experiments strongly suggested that thecleavage by I of C4b bound
to the human red cells was mediated by the cofactor activity of CRI within the
same cell membrane, rather than that of CRI on the surface of neighboring
cells. For example, the introduction of threefold more HE or 25 times more
purified CRI into reaction mixtures containing HEAC14 and variable concen-
trations of I did not enhance the extent of cleavage of C4b (Fig. 4a). Neither
were the kinetics of release of radiolabeled C4c at a fixed concentration of I (5
,tag/ml) enhanced by purified CRI or by additional HE (Fig. 4b). Even more
striking was the fact that a 10-fold variation in the concentration of HEAC14
had no effect on the extent of cleavage; that is, the reaction was not enhanced
by greatly increasing the frequency of cell collisions and encounters between
CRI and exogenous Cob (Fig. 5).
Inhibitory Effect ofC4b Deposition on Extrinsic Cofactor Activity of CR 1.
￿
Next we
studied the effect of C4b deposition on the extrinsic cofactor activity of CR 1 of
human erythrocytes. The assay consisted of measuring the cofactor activity of
several different preparations of human red cells; HE, HEC1, HEC14, on the
release of C3 fragments (C3c) from SE bearing radiolabeled C3b. As shown in
Fig. 6, HE plus I (but not HE, HEC14, or I alone) released >40% of the labeled
C3b bound to SE after 1 h of incubation of the mixture at 37°C . HEA or
HEACI plus I had the same effect as HE plus I. However, after C4 deposition
on the human red cells, the cleavage of the exogenous C3b was profoundly
inhibited. The inhibitory effect increased with the amount of deposited C4b; for





Removal of CR1-C4b complexes by immunoprecipitation with anti-C4 . The NP-
40 extract of DSP-treated HEAC14 was incubated with anti-C4 IgG (lane 1), normal IgG (lane
2) or buffer alone (lane 3) . The mixtures were then incubated with protein A-Sepharose
beads to remove immune complexes . The beads were separated by centrifugation and the
supernatants were subjected to SDS-PAGE and Western blotting as described in Fig . 1. The
treatment with anti-C4 IgG removed the high-Mr bands containing CR1, indicating that they
originated from the crosslinking of C4b and CR1 .
extrinsic C3b, and 3,000 molecules of deposited C4b inhibited the cleavage
almost completely .
Discussion
Classical pathway activation of the complement cascade on or close to the
surface of red cells leads to the deposition ofC4b on their membranes . That this
also occurs under physiological conditions is shown by the presence of C4b
fragments (C4d) on all normal human or mouse erythrocytes, where they have1382
FIGURE 3.
￿
CRI-dependent cleavage of HE-bound C4b by factor I. HEAC14 cells bearing
1,000 molecules of radiolabeled C4b per cell (5 X 10' cells/ml in DGVB2+) were incubated
with increasing amounts of factor I alone(0-10 fag/ml) (0), or factor I plus monoclonal anti-
CRI (57F, 57H, and 44D; 12.5 mg/ml each) (A), anti-DAF (IAIO, IIH6, and VIIIA7; 12.5
,ug/ml each) (0), or anti-malaria parasite (3D11; 37.5 jig/ml) (0). After 2 h incubation at
37 °C, the cells were removed by centrifugation and thecounts released into the supernatants
were measured. Anti-CRI mAbs inhibited the factor I-mediated release of C4 fragments.









Cleavage by factor I of HE-bound C4b is dependent on intrinsic association of
C4b with CRI within the same cell. A, HEAC14 cellsbearing 1,000 molecules of radiolabeled
C4b per cell (5 X 10' cells/ml in DGVB2+, containing -10 ng/ml CR1) were incubated with
increasing amounts of factor I alone (0-10 ttg/ml) (0), factor I plus purified CR1 (250 ng/ml
(p), or factor I plus HE (1 .5 X 108 cells/ml) (p). After 2 h incubation at 37°C, extent of
cleavage of C4b was determined by measuring the release of C4c radioactive fragments.
Addition ofpurified CRI or HE didnotenhance the cleavage. B, HEAC14 cellsbearing 1,000
molecules labeled C4b per cell (5 X 10' cell/ml) were incubated at 37°C with factor I alone
(5 ,ug/ml) (0), factor I plus purified CRI (250 ng/ml) (A), factor I plus HE (1 .5 X 108cells/ml)
(0), DGVB2+ alone(0), CR 1 alone (A), or HE alone (/). At differenttime intervals, theextent
of cleavage of C4b was determined. Addition of purified CRI or HE hadno significant effect
on the rate of cleavage.
been identified as blood group antigens (22, 23). The mechanisms that regulate
the function of membrane-bound Cob and which lead to its fragmentation on
autologous cell membranes are poorly understood. Although DAF prevents the
binding of C2 to C4b and the formation of the C3-convertase C4b, 2a, it has no
effect on the structure of Cob (4).
A few studies have dealt with the fate of Cob bound to heterologous cells. The
«' chain of human C4b deposited on the membrane of SE can be cleaved by the
serum enzyme I (20). However, during the initial phases of activation of the
cascade when the number of deposited Cob molecules is small, the fragmentation
















Effect of varying the concentration of HEAC14 cells on the C4b cleavage when
the concentration of factor I is kept constant. 10' cells of HEAC14 bearing 1,000 molecules
of radiolabeled C4b were suspended in various volumes (0.2-2 ml) of DGVB" containing
factor I at aconcentration of 1.5 Ag/ml (O)or DGVB" (0). After I h incubation at 37°C, the
amountsof radiolabeled C4b fragments released were determined. The cleavage of C46 was
not enhanced at higher concentration of the cells, suggesting that the cleavage was not











Concentration of HEAC14 (x10'r cellslml)
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Molecules of Cob per
FIGURE 6.
￿
Inhibition by intrinsic C4b of the extrinsic cofactor activity of CR1. SEAC1423
cells (5 X 10' cells/ml in DGVB2+) bearing 1,800 molecules of radiolabeled Cab per cell were
incubated for 1 h at 37°C with HEAC14 cells (5 X 10' cells/ml) bearing increasing amounts
of C46 in the presence (O) or absence (*) of factor I (5 Ag/ml). The number of bound C4b
molecules in each cell intermediate wascalculated from the results ofpreliminary experiments
in which the same concentrations of radiolabeled C4 were used. HE, HEA, and HEAC1,
either alone or with factor I, were included as controls. In the presence of factor I plus HE,
HEA, or HEAC1, ^-42% of C3 radiolabel was released. The cofactor activity of HEAC14 cells
decreasedand the decrease was dependent on the dose of C4b bound per cell.
cofactor C4bp, or by the extrinsic activity of human CR1, but this only occurs
when the number of bound C4b on SE is high, or after amplification of the
cascade and C3b deposition (24, 25).
The main new findings of this paper are that small numbers of human C4b
molecules deposited on human erythrocytes bind to endogenous CR1, and that
the bound C4b is cleaved by serum factor 1. The intrinsic association between
CR1 and the membrane-bound C4b was demonstrated by the formation of
complexes between the two molecules when HEAC14 were treated with a
bifunctional crosslinking reagent (DSP).
The substrate for the enzymatic activity of I was primarily the C4b bound
endogenously to CRI , and not C4b bound to CR1 present on the surface of a
different HEC14 cell. Indeed, the kinetics or the extent of cleavage ofC4b were1384
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not affected by greatly increasing the concentration of extrinsic CR1 in the
incubation mixture by adding either HE or purified CR1 . In these experiments,
we purposely deposited limited amounts of C4b on the red cells (a maximum of
1,000 molecules), in order to better mimic the initial phases of complement
activation in vivo. It is likely that extrinsic CRI would also act on HEAC14 if a
larger number of C4b molecules had been deposited on the human red cells.
Furthermore, the extent of cleavage was not affected by increasing the concen-
tration of HEC14 cells and therefore the frequency of cell collisions.
Most of the CRI of the erythrocytes could be crosslinked to C4b when 1,900
molecules of C4b were deposited on the red cell surface. Although a relatively
short time (30 min at room temperature) elapsed between the deposition of C4b
and the addition of DSP, the efficiency of crosslinking was high . This suggests
that the encounters (presumably random) between CR 1 and C4b led to the
formation of stable CRI-C4b complexes. The high avidity of deposited C4b for
endogenous CRI is also highlighted by the concomitant loss of the extrinsic
cofactor activity of the complement receptor for exogenous target-bound C3b
(Fig. 6). This is unexpected, since an HE contains only several hundred molecules
of CRI, which have much higher binding avidity for C3b than for fluid-phase
C4b (20) or C4b deposited extrinsically onto SE (26). Nonetheless, it is conceiv-
able that other factors enhance the binding of C4b to CR 1 on the surface of the
lipid bilayer, i .e ., the geometry of the respective binding domains may favor the
interaction, or alternatively, the dissociation of the formed complexes may be
restricted by secondary events or by other neighboring molecules.
The precise composition of the CRI-C4b complexes is unknown. When ex-
tracts of membranes of the DSP-treated HEAC14 cells were subjected to SDS-
PAGE, two high-Mr bands, containing C4b and CRI, were detected by Western
blotting. One band had Mr ^-400,000, and must contain only one molecule each
of CR1 (200,000 Mr) and C4b (190,000 M,). The second band, of higher M,,
could represent complexes between C4b clusters with CRI, or could contain
additional membrane molecules. Although DAF can also bind intrinsically to
C4b, it is unlikely that it is included in this band. Using the same methods, we
found that most of the DAF-C4b complexes have Mr of 250,000-300,000 (11).
Moreover, the DAF-C4b complexes formed on human red cells were only
detected by this technique when the number of deposited C4b molecules was >3
x 103 per cell (11), while the C4b-CRI-containing bands could be seen in cells
bearing 10 times less C4b.
On the basis of the present and prior observations, we speculate (Fig. 7) that
both DAF and CRI act endogenously to inactivate the function of C4b and
prevent the progression of the cascade. DAF, which is anchored on the cell
membrane via phosphatidylinositol (27, 28), may move more rapidly than CR I
on the plane of the membrane . DAF binding prevents the formation of the C3
convertase C4b,2a . The cleavage of C4b and the generation of the inactive C4d
fragments (that is, the Chido and Rodgers blood groups [22]) occurs after the
concerted activities of endogenous CR1 and serum factor 1. Because neither
DAF nor CRI has detectable binding affinity for the remaining membrane-
bound fragment, C4d, we presume that the membrane inhibitors will become
free to interact with additional ligands. This hypothesis does not distinguishC4 b Deposition on Human Red Cell Glyaophorin
￿
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Schematic representation ofthe proposed mechanismofprocessing ofautologous
erythrocyte-bound C4b by complement regulatory proteins. TheCRI boundto C4bis shown
slightly tilted only to simplify thedrawingof the complexes.
between the fate of the two isotypes of C4b (29) nor take into account the fact
that they may form covalent bonds with different structures of the acceptor
membrane molecules (30-32).
Others have shown that C3b bound to human erythrocytes can be attacked by
I, and that this reaction is CRI dependent, but their experiments did not
distinguish between the intrinsic and extrinsic activities of the receptor (1).
Because ofthe central role ofC3b in initiation andamplification ofthe alternative
pathway, and the observed deficiencies of CR1 in some autoimmune diseases
(33-35), this question has considerable interest. In the light of the present
findings and the fact that CRI has higher bindingaffinity for extrinsically bound
C3b than for C4b, it seems likely that CRI will also function endogenously to
inactivate C3b. This point, however, remains to be established.
Activation of the classical complement pathway on the membrane of autolo-
gous cells results in the deposition of C4b on their surface and in the assembly
of the C3 convertase C4b2a, one ofthe amplifying enzymes of the cascade. Here
we study the sequence of events leading to irreversible inactivation of the
potentially harmful C4b bound to human red cells. We show that deposited C4b
interacts endogenously with complement receptor type 1 (CR1) present on the
membrane of the same red cell. Complexes containing CRI and C4b are found1386
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in extracts of membranes of Cob-bearing red cells after treatment of the intact
cells with a bifunctional crosslinking reagent. The amount of complexed CR1
increases with the number of deposited C4b molecules. Only small amounts of
free CR1 are observed on red cells bearing as few as 1,900 molecules of C4b,
suggesting that the binding avidity between C4b and endogenous CR 1 is high .
In agreement with this observation, we find that the deposited C4b inhibits the
exogenouscofactor activity of thered cell CR 1 for the factor I-mediated cleavage
of target-bound clustered C3b.
The C4b bound to the human red cells is cleaved by the serum enzyme
C3b/C4b inactivator (factor I) and a large fragment (C4c) is released in the
incubation medium . The cleavage is totally inhibited by mAbs against CR1,
showing that the complement receptor is an essential cofactor for the activity of
I. When the number of bound C4b per red cell is relatively small (<1,000
molecules) the substrate for the enzymatic activity of factor I is mostly or
exclusively the C4b bound endogenously to CR1 . Indeed, the kinetics or the
extent of cleavage of C4b are not affected by greatly augmenting the concentra-
tion of exogenous CR1 or of C4b-bearing red cells in the incubation mixture,
thereby increasing the frequency of collisions between CR1 on the surface of
one cell with C4b deposited on the membrane of a different cell .
On the basis of the present and prior observations, we speculate that both
DAF and CR1 act endogenously to inactivate the function of autologous red
cell-bound C4b and prevent the progression of the cascade. DAF binding
prevents the formation of the C3 convertase, C4b2a. The cleavage and irre-
versible inactivation of C4b only occurs after the concerted activities of endoge-
nous CR1 and serum factor I. Because the remaining membrane-bound C4d
fragments (that is, the Chido and Rodgers blood groups) have no demonstrable
binding affinity for DAF or CR1, these membrane proteins will be free to
interact with additional bound ligands.
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